Greater intraprostatic heterogeneity was associated with late grade 2+ GU toxicity. Given the high correlation of prostate volume with toxicity, SBRT dose parameters should be individualized and risk-adapted based on normalized prostate volumes, including a V50 not to exceed 9% of the prostate. The urethra is an important organ at risk, and the 42-Gy dose-volume should be limited to 2 mL, while bladder dose-volumes appear to be poor predictors of GU grade 2+ toxicity.
Zachary A. Seymour, MD, Li Zhang, PhD, Albert J. Chang, MD, I-Chow J. Hsu, MD, Alexander R. Gottschalk, MD, PhD; Department of Radiation Oncology, Cancer Center, University of California, San Francisco
PURPOSE AND OBJECTIVES: To evaluate dose-volume relationships of genitourinary (GU) toxicity after stereotactic body radiotherapy (SBRT) for prostate cancer to determine optimal cut points for dosimetric parameters based on prostatic volume.
MATERIALS AND METHODS: Fifty-one of 56 patients treated with SBRT for prostate cancer had evaluable dose-volume histograms. All patients were treated in a uniform manner, receiving a total dose of 38 Gy in 4 fractions. Acute, late, and overall GU toxicities were documented according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE v4). Dose volumes were assessed via receiver operating characteristic (ROC) curves to determine optimal cut points at 0.5-Gy dose-volume intervals, and probabilities of toxicity for each cut point were produced. Only dose volumes with a sensitivity and specificity > 0.65 were considered for analysis of GU grade 2+ toxicity.
RESULTS: The median age at treatment was 68 years, and median prostate volume was 45.4 mL. The median prescription isodose line was 68%. The median clinical follow-up was 35.49 months. Acute and late grade 2+ GU toxicities occurred in 35.7% and 23.2%, respectively, with only 2 grade 3 GU toxicities. Overall toxicity was associated with baseline prostate volume (continuous, P = .006; hazard ratio [HR] = 1.06; 95% confidence interval [CI], 1.02–1.10) with an overall risk of 39% for grade 2+ toxicity in patients with prostate volumes > 45 mL (AUC 0.722, sensitivity 67%, specificity 71%). The probability of late grade 2+ GU toxicity was associated with absolute and normalized prostate volumes across doses from 46–50 Gy, suggestive of increasing late toxicity with intraprostatic heterogeneity. Normalized V50 Gy of 9% was the strongest normalized prostate volume associated with a 19% late grade 2+ GU toxicity rate (AUC 0.763, sensitivity 82%, specificity 68%). Urethra 42 Gy volume was also associated with grade 2+ toxicity with an optimal cutoff of 2.1 mL (AUC 0.62, sensitivity 82%, specificity 70%, probability 19%). No bladder volume cut points were strongly associated with late or overall GU grade 2+ toxicity.
CONCLUSIONS: Greater intraprostatic heterogeneity was associated with late grade 2+ GU toxicity. Given the high correlation of prostate volume with toxicity, SBRT dose parameters should be individualized and risk-adapted based on normalized prostate volumes, including a V50 not to exceed 9% of the prostate. The urethra is an important organ at risk, and the 42-Gy dose-volume should be limited to 2 mL, while bladder dose-volumes appear to be poor predictors of GU grade 2+ toxicity.
Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.